Inogen (INGN) Stake Lessened by Chicago Equity Partners LLC

Chicago Equity Partners LLC decreased its holdings in Inogen (NASDAQ:INGN) by 34.6% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 14,905 shares of the medical technology company’s stock after selling 7,890 shares during the period. Chicago Equity Partners LLC owned approximately 0.07% of Inogen worth $1,831,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of INGN. Louisiana State Employees Retirement System increased its stake in shares of Inogen by 7.2% in the 4th quarter. Louisiana State Employees Retirement System now owns 7,400 shares of the medical technology company’s stock valued at $881,000 after purchasing an additional 500 shares during the last quarter. Schwab Charles Investment Management Inc. grew its position in Inogen by 3.0% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 79,600 shares of the medical technology company’s stock worth $9,479,000 after acquiring an additional 2,327 shares during the last quarter. Acadian Asset Management LLC grew its position in Inogen by 31.5% during the 4th quarter. Acadian Asset Management LLC now owns 6,980 shares of the medical technology company’s stock worth $832,000 after acquiring an additional 1,674 shares during the last quarter. Steward Partners Investment Advisory LLC grew its position in Inogen by 1,000.0% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 1,100 shares of the medical technology company’s stock worth $130,000 after acquiring an additional 1,000 shares during the last quarter. Finally, Sumitomo Mitsui Asset Management Company LTD bought a new stake in Inogen during the 4th quarter worth $1,776,000. Institutional investors own 99.40% of the company’s stock.

In other Inogen news, Director Loren L. Mcfarland sold 2,125 shares of the company’s stock in a transaction dated Friday, May 11th. The stock was sold at an average price of $181.44, for a total value of $385,560.00. Following the sale, the director now owns 3,114 shares in the company, valued at approximately $565,004.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Scott Wilkinson sold 9,198 shares of the company’s stock in a transaction dated Tuesday, May 1st. The shares were sold at an average price of $170.35, for a total value of $1,566,879.30. The disclosure for this sale can be found here. Insiders sold a total of 49,148 shares of company stock worth $6,778,955 in the last quarter. Corporate insiders own 5.29% of the company’s stock.

A number of equities research analysts recently weighed in on the company. JPMorgan Chase boosted their price objective on Inogen from $150.00 to $180.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 1st. ValuEngine upgraded Inogen from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, May 2nd. Leerink Swann restated an “outperform” rating and set a $170.00 price objective (up previously from $150.00) on shares of Inogen in a research report on Tuesday, May 1st. Piper Jaffray boosted their price objective on Inogen to $190.00 and gave the stock an “overweight” rating in a research report on Monday, April 30th. Finally, Zacks Investment Research lowered Inogen from a “buy” rating to a “hold” rating in a research report on Wednesday, February 7th. One equities research analyst has rated the stock with a hold rating, three have given a buy rating and three have issued a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $178.00.

Inogen opened at $182.99 on Friday, according to Marketbeat. Inogen has a 12 month low of $179.91 and a 12 month high of $180.99. The stock has a market capitalization of $3.78 billion, a price-to-earnings ratio of 139.69, a P/E/G ratio of 4.50 and a beta of 1.01.

Inogen (NASDAQ:INGN) last released its quarterly earnings results on Monday, April 30th. The medical technology company reported $0.48 EPS for the quarter, beating analysts’ consensus estimates of $0.29 by $0.19. Inogen had a return on equity of 14.81% and a net margin of 9.36%. The firm had revenue of $79.05 million for the quarter, compared to analyst estimates of $63.86 million. During the same quarter in the previous year, the company posted $0.27 EPS. The business’s revenue was up 50.6% on a year-over-year basis. equities research analysts expect that Inogen will post 1.76 earnings per share for the current fiscal year.

About Inogen

Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. The company's oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

Want to see what other hedge funds are holding INGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inogen (NASDAQ:INGN).

Institutional Ownership by Quarter for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.



Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit